You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》雅培藥廠季度多賺1.2倍 受惠非新冠業務復甦
阿思達克 07-23 10:42
美國雅培藥廠(Abbott)(ABT.US)公佈今年第二季度業績。季度淨收益11.89億美元,按年升121.5%。每股季度攤薄純利66美仙,經調整後爲1.17美元,高於市場預期的1.02美元。季度淨銷售102.23億美元,按年升39.5%。

公司季度受惠非新冠檢測業務及醫療設備銷售反彈。扣除新冠檢測的季度銷售錄得11%內生增長,扣除新冠及全球檢測收益按年升42.5%,醫療設備銷售按年升51.3%,受心臟設備業務增長支撐。新冠檢測產品的銷售則由首季的22億美元,降至次季的13億美元。

公司重申全年經調整每股持續經營業務純利介乎4.3至4.5美元的預測。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account